ArticleFrontiers in psychiatry2026
Case Report: Neuropsychiatric instability in structurally compromised CNS Erdheim-Chester disease: a diagnostic and management challenge.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis involving multiple systems, with central nervous system (CNS) involvement present in a significant subset. Neuropsychiatric symptoms such as cognitive decline, mood disturbances, and psychosis have been documented. However, sensitivity to psychotropic medications in CNS-involved ECD remains underreported. This case highlights a multi-mechanistically compromised CNS posing diagnostic and therapeutic challenges by such sensitivity. Case presentation: A 50-year-old woman with biopsy-confirmed ECD and CNS involvement presented with persistent neuropsychiatric symptom confusion, psychosis, cognitive decline, mood lability, and agitation despite radiologic remission following cladribine and radiotherapy. She exhibited marked sensitivity to multiple psychotropics: haloperidol induced QTc prolongation; risperidone and aripiprazole triggered akathisia and insomnia; olanzapine caused hypotension; chlorpromazine and quetiapine led to oversedation; and benzodiazepines paradoxically worsened agitation. Only valproic acid was tolerated. Factors such as previous chemotherapy, brain radiotherapy, hypernatremia, endocrine dysfunction, and a family history of psychiatric illness were suspected to have a role in predisposition. Imaging showed lesions of the hypothalamus, pituitary stalk, and mesial temporal lobes. Persistent symptoms shared features with Lewy Body Dementia and raised the diagnostic ambiguity. Conclusion: To our knowledge, this is one of the first detailed reports to describe heightened neuropsychiatric instability and psychotropic intolerance in a patient with a compromised CNS through several suspected mechanisms. The case underscores the need for multidisciplinary care and cautious psychiatric management in patients with a compromised CNS. Clinicians should suspect psychotropic sensitivity in cases with paradoxical responses and consider systemic causes such as ECD as a possible contributor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.